Starting in 2024: The Pseudovax first-in-man vaccine trial for patients with pseudomyxoma peritonei

Pseudomyxoma peritonei (PMP) is a rare, slow-growing abdominal cancer with no efficacious treatment options in non-resectable and recurrent cases. Activating mutations in the GNAS oncogene are remarkably frequent in PMP and the mutated gene product, guanine nucleotide-binding protein α subunit (Gsα), is a potential tumor neo-antigen, presenting an opportunity for targeting by a therapeutic cancer vaccine. 

https://kreftforeningen.no/aktuelt/stjernene-gir-nytt-hap-om-en-felles-framtid/

https://oslo-universitetssykehus.no/om-oss/nyheter/ny-behandling-for-pasienter-med-kreft-i-blindtarmen?fbclid=IwAR32T3Y7MEIBHvCylRDy7Urs4dbVG6Cf5uPG075GuNLw3eZa9jgLLa4es6k

see the video here 

BM7PE immunotoxin phase I/II trial (https://clinicaltrials.gov/)

This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aims to examine overall survival ≥ 9.3 months.

Radspherin phase I/II trial (https://clinicaltrials.gov/)

This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma following complete CRS (cytoreduction score CC-0) and HIPEC.

NIPEC-OXA trial (https://clinicaltrials.gov/)  

Feasibility study regarding 20 Patients with peritoneal metastases from colorectal cancer treated with cytoreductive surgery and HIPEC and subsequently with 4 courses of normothermic intraperitoneal chemotherapy - long term (NIPEC-OXA) with oxaliplatin.

NAVI-LARRC trial (https://clinicaltrials.gov/) 

The aim of this study was to investigate feasibility of computer navigation-assisted surgery in particularly difficult cases of locally advanced (LARC) and recurrent (LRRC) rectal cancer where the standard surgical strategy is expected to result in incomplete tumour removal. The investigators hypothesized that computer navigation-assisted surgery can facilitate improved anatomic orientation in the pelvis enabling tumour removal with free margins in these cases.

METIMMOX trial (https://clinicaltrials.gov/)

This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC).